Pathogenetic substantiation of a differential approach to the treatment of endometrial hyperplasia in women with abdominal obesity
DOI:
https://doi.org/10.12775/JEHS.2025.80.60415Keywords
endometrial hyperplasia, insulin resistance, abdominal obesity, THF-alpha, leptin, sex hormone binding protein, hyperandrogenism, aromatase, endometrium, levonorgestrel, metformin, oxidative stress, cytokines, Vitex agnus castus, “Epigallocatechin”, “сucurmin”Abstract
Background: Endometrial hyperplasia is a precursor to endometrial adenocarcinoma. According to the Global Cancer Observatory 2019, endometrial cancer affects 382,000 women worldwide per year. With timely detection and treatment of endometrial hyperplasia and modification of the factors that lead to excessive proliferation of the internal lining of the uterus, it will be possible to reduce the incidence and preserve the fertility of women of reproductive age. Excessive estrogen is the main cause of endometrial hyperplasia. While the leading mechanism of excessive endometrial proliferation is a disruption in the cyclical change in the ratio of production of the main female hormones estrogen/progesterone. Obesity is a pandemic of the 21st century. Abdominal obesity is the most metabolically dangerous variant of it, as it is characterized by distorted endocrine function, which disrupts the normal functioning of the hypothalamic-pituitary-ovarian system in women. and is also involved in impaired cellular sensitivity to insulin and low-grade chronic inflammation. Methods: This literature review summarizes the impact of abdominal obesity on the female reproductive system and explains the pathogenetic influence of abdominal obesity on the development, progression and recurrence of endometrial hyperplasia. Results: This review summarizes the importance of modern pathogenetic treatment of endometrial hyperplasia in women with abdominal obesityConclusion:. It was found that the use of first-line drugs together with drugs that increase insulin sensitivity, lifestyle modification and the use of herbal remedies containing Vitex agnus castus can have a positive effect on the treatment of endometrial hyperplasia, and also report a positive effect on improving the quality of life and avoiding recurrence of the disease in women with abdominal obesity
References
1. Ring, Kari L. MD; Mills, Anne M. MD; Modesitt, Susan C. MD. Endometrial Hyperplasia. Obstetrics & Gynecology 140(6):p 1061-1075, December 2022. | DOI: 10.1097/AOG.0000000000004989
2. Szukiewicz, D. Current Insights in Prolactin Signaling and Ovulatory Function. Int. J. Mol. Sci. 2024, 25, 1976. https://doi.org/10.3390/ijms25041976
3. Association of prolactin and insulin with obesity in women with polycystic ovarian syndrome Lavanya K.1 , Palaniappan N.2 , Vinodhini V.M.3 , Mahesh Kumar K.4 , Santhi Silambanan1 1Department of Biochemistry, 2Department of Obstetrics and Gynaecology, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, 600116, Tamil Nadu, India 3Department of Biochemistry, SRM Medical College Hospital and Research, Mahatma Gandhi Rd, Potheri, SRM Nagar, Kattankulathur, Tamil Nadu, India 4Department of Physiology and Biochemistry, Government Yoga and Naturopathy Medical College and Hospital, Chennai, 600106, Tamil Nadu, India (Received: March 2022 Revised: November 2022 Accepted: December 2022) DOI: https://doi.org/10.51248/.v42i6.1613
4. Zhong, X., Li⋅, Y., Liang, W. et al. Clinical and metabolic characteristics of endometrial lesions in polycystic ovary syndrome at reproductive age. BMC Women's Health 23, 236 (2023). https://doi.org/10.1186/s12905-023-02339-7
5. Johnson J, Daley D, Tarta C and Stanciu PI: Risk of endometrial cancer in patients with polycystic ovarian syndrome: A meta‑analysis. Oncol Lett 25: 168, 2023: 168. https://doi.org/10.3892/ol.2023.13754
6. Nees, L.K., Heublein, S., Steinmacher, S. et al. Endometrial hyperplasia as a risk factor of endometrial cancer. Arch Gynecol Obstet 306, 407–421 (2022). https://doi.org/10.1007/s00404-021-06380-5
7. Beverley Balkau, John E. Deanfield, Jean-Pierre Després, Jean-Pierre Bassand, Keith A.A. Fox, Sidney C. SmithJr, Philip Barter, Chee-Eng Tan, Luc Van Gaal, Hans-Ulrich Wittchen, Christine Massien and Steven M. Haffner International Day for the Evaluation of Abdominal Obesity (IDEA)A Study of Waist Circumference, Cardiovascular Disease, and Diabetes Mellitus in 168 000 Primary Care Patients in 63 Originally published 23 Oct 2007https://doi.org/10.1161/CIRCULATIONAHA.106.676379 Circulation. ;116:1942–1951
8. Kuryłowicz, A. Estrogens in Adipose Tissue Physiology and Obesity-Related Dysfunction. Biomedicines 2023, 11, 690. https://doi.org/10.3390/biomedicines11030690 https://doi.org/10.3390/biomedicines11030690
9. Qu, X.; Donnelly, R. Sex Hormone-Binding Globulin (SHBG) as an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome. Int. J. Mol. Sci. 2020, 21, 8191. https://doi.org/10.3390/ijms21218191
10. Deepika Dhawan, Sheel Sharma,Abdominal Obesity, Adipokines and Non-communicable Diseases,The Journal of Steroid Biochemistry and Molecular Biology,Volume 203,2020,105737,ISSN 0960-0760,https://doi.org/10.1016/j.jsbmb.2020.105737.
11. Nan Mu, Yuanxi Zhu, Yingmei Wang, Huiying Zhang, Fengxia Xue,Insulin resistance: A significant risk factor of endometrial cancer,Gynecologic Oncology,Volume 125, Issue 3,2012,Pages 751-757,ISSN 0090-8258, https://doi.org/10.1016/j.ygyno.2012.03.032.
12. Professor Nikolaos Tzenios Ph.D., FRSPH, FRSM,FAAMFM,FWAMS, FMRS, AcIASS, mRSB, DABAAHP1, Dr. Mary E. TAZANIOS, MD ObGyn2, and Mohamad Chahine, Ph.D Obesity and endometrial cancer: the role insulin resistance and adipokines 2023 02/09/2023DOI:https://doi.org/10.58676/sjmas.v1i2.12
13. Serdar Kaya,Başak Kaya,Hüseyin Levent Keskin,Burcu Kayhan Tetik &Filiz Ayşe Yavuz Pages 176-183 | Published 04 Oct 2018 Is there any relationship between benign endometrial pathologies and metabolic status? https://doi.org/10.1080/01443615.2018.1469606
14. Agnew H, Kitson S, Crosbie EJ. Interventions for weight reduction in obesity to improve survival in women with endometrial cancer. Cochrane Database of Systematic Reviews 2023, Issue 3. Art. No.: CD012513. DOI: 10.1002/14651858.CD012513.pub3. Accessed 25 April 2024.
15. Kursad Unluhizarci, Zuleyha Karaca, and Fahrettin Kelestimur World J Diabetes. 2021 May 15; 12(5): 616–629.Role of insulin and insulin resistance in androgen excess disorders Published online 2021 May 15. doi: 10.4239/wjd.v12.i5.616
16. Joselyn Rojas, Mervin Chávez, Luis Olivar, Milagros Rojas, Jessenia Morillo, José Mejías, María Calvo, Valmore Bermúdez, "Polycystic Ovary Syndrome, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth", International Journal of Reproductive Medicine, vol. 2014, Article ID 719050, 17 pages, 2014. https://doi.org/10.1155/2014/719050
17. G B Phillips, C H Tuck, T Y Jing, B Boden-Albala, I F Lin, N Dahodwala, R L Sacco; Association of hyperandrogenemia and hyperestrogenemia with type 2 diabetes in Hispanic postmenopausal women.. Diabetes Care 1 January 2000; 23 (1): 74–79. https://doi.org/10.2337/diacare.23.1.74
18. Yong W, Wang J, Leng Y, Li L, Wang H. Role of Obesity in Female Reproduction. Int J Med Sci. 2023 Jan 31;20(3):366-375. doi: 10.7150/ijms.80189. PMID: 36860674; PMCID: PMC9969507.
19. Yang Zhang, Weidong Jin, Dongyun Zhang, Changhai Lin, Haiyan He, Fengxin Xie, Lixia Gan, Weiling Fu, Lixiang Wu, Yongzhong Wu, "TNF-α Antagonizes the Effect of Leptin on Insulin Secretion through FOXO1-Dependent Transcriptional Suppression of LepRb in INS-1 Cells", Oxidative Medicine and Cellular Longevity, vol. 2022, Article ID 9142798, 16 pages, 2022. https://doi.org/10.1155/2022/9142798
20. Sangeeta Nair, HoVan Nguyen, Salama Salama, Ayman Al-Hendy, "Obesity and the Endometrium: Adipocyte-Secreted Proinflammatory TNFα Cytokine Enhances the Proliferation of Human Endometrial Glandular Cells", Obstetrics and Gynecology International, vol. 2013, Article ID 368543, 7 pages, 2013. https://doi.org/10.1155/2013/368543
21. Jessica A. Breznik, Kevin P. Foley, Dhanyasri Maddiboina, Jonathan D. Schertzer, Deborah M. Sloboda, Dawn M. E. Bowdish; Effects of Obesity-Associated Chronic Inflammation on Peripheral Blood Immunophenotype Are Not Mediated by TNF in Female C57BL/6J Mice. Immunohorizons 1 June 2021; 5 (6): 370–383. https://doi.org/10.4049/immunohorizons.2100038
22. Catalano S, Marsico S, Giordano C, Mauro L, Rizza P, Panno ML, Andò S. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem. 2003 Aug 1;278(31):28668-76. doi: 10.1074/jbc.M301695200. Epub 2003 May 6. PMID: 12734209.)
23. Zheng L, Yang L, Guo Z, Yao N, Zhang S and Pu P (2024) Obesity and its impact on female reproductive health: unraveling the connections. Front. Endocrinol. 14:1326546. doi: 10.3389/fendo.2023.1326546
24. Gwen V Childs, Angela K Odle, Melanie C MacNicol, Angus M MacNicol, The Importance of Leptin to Reproduction, Endocrinology, Volume 162, Issue 2, February 2021, bqaa204, https://doi.org/10.1210/endocr/bqaa204
25. Ramon-Krauel, M., Leal-Witt, M.J., Osorio-Conles, Ó. et al. Relationship between adiponectin, TNFα, and SHBG in prepubertal children with obesity. Mol Cell Pediatr 8, 3 (2021). https://doi.org/10.1186/s40348-021-00113-z
26. Simó R, Barbosa-Desongles A, Sáez-Lopez C, Lecube A, Hernandez C, Selva DM. Molecular Mechanism of TNFα-Induced Down-Regulation of SHBG Expression. Mol Endocrinol. 2012 Mar;26(3):438-46. doi: 10.1210/me.2011-1321. Epub 2012 Feb 2. PMID: 22301786; PMCID: PMC5417125.
27. Salama SA, Kamel MW, Diaz-Arrastia CR, Xu X, Veenstra TD, Salih S, Botting SK, Kumar R. Effect of tumor necrosis factor-alpha on estrogen metabolism and endometrial cells: potential physiological and pathological relevance. J Clin Endocrinol Metab. 2009 Jan;94(1):285-93. doi: 10.1210/jc.2008-1389. Epub 2008 Oct 28. PMID: 18957495; PMCID: PMC2630861.
28. Sangeeta Nair, HoVan Nguyen, Salama Salama, Ayman Al-Hendy, "Obesity and the Endometrium: Adipocyte-Secreted Proinflammatory TNFα Cytokine Enhances the Proliferation of Human Endometrial Glandular Cells", Obstetrics and Gynecology International, vol. 2013, Article ID 368543, 7 pages, 2013. https://doi.org/10.1155/2013/368543
29. Mittermeier T, Farrant C, Wise MR. Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia. Cochrane Database of Systematic Reviews 2020, Issue 9. Art. No.: CD012658. DOI: 10.1002/14651858.CD012658.pub2. Accessed 24 April 2024.
30. Rachel S. Mandelbaum, Marcia A. Ciccone, David J. Nusbaum, Mahdi Khoshchehreh, Heena Purswani, Elise B. Morocco, Meghan B. Smith, Shinya Matsuzaki, Christina E. Dancz, Begum Ozel, Lynda D. Roman, Richard J. Paulson, Koji Matsuo,Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy,American Journal of Obstetrics and Gynecology, Volume 223, Issue 1,2020,Pages 103.e1-103.e13,ISSN 0002-9378, https://doi.org/10.1016/j.ajog.2019.12.273.
31. Gena M. Elassall, Esraa G. Sayed, Nada A. Abdallah, Mariam M. El-Zohiry, Ahmed A. Radwan, AlBatool M. AlMahdy, Ahmed S. Sedik, Hossam Aldein S Abd Elazeem, Sherif A. Shazly,Levonorgestrel-releasing intrauterine system versus systemic progestins in management of endometrial hyperplasia: A systemic review and meta-analysis,Journal of Gynecology Obstetrics and Human Reproduction,Volume 51, Issue 8, 2022,https://doi.org/10.1016/j.jogoh.2022.102432.
32. Chae-Kim J, Garg G, Gavrilova-Jordan L, et alOutcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysisInternational Journal of Gynecologic Cancer 2021;31:1499-1505. https://doi.org/10.1136/ijgc-2021-002699
33. Uccella, S.; Zorzato, P.C.; Dababou, S.; Bosco, M.; Torella, M.; Braga, A.; Frigerio, M.; Gardella, B.; Cianci, S.; Laganà, A.S.; et al. Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women. Medicina 2022, 58, 1256. https://doi.org/10.3390/medicina58091256
34. Ravi RD, Kalra J, Srinivasan R, Bagga R, Jain V, Suri V, Sachdeva N. A Randomized Clinical Trial of Levonorgestrel Intrauterine System with or without Metformin for Treatment of Endometrial Hyperplasia without Atypia in Indian Women. Asian Pac J Cancer Prev. 2021 Mar 1;22(3):983-989. doi: 10.31557/APJCP.2021.22.3.983. PMID: 33773565; PMCID: PMC8286694.
35. Oróstica, M.L.; Astorga, I.; Plaza-Parrochia, F.; Poblete, C.; Carvajal, R.; García, V.; Romero, C.; Vega, M. Metformin Treatment Regulates the Expression of Molecules Involved in Adiponectin and Insulin Signaling Pathways in Endometria from Women with Obesity-Associated Insulin Resistance and PCOS. Int. J. Mol. Sci. 2022, 23, 3922. https://doi.org/10.3390/ijms23073922
36. Soldat-Stanković, V., Popović-Pejičić, S., Stanković, S. et al. The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial. J Endocrinol Invest 45, 583–595 (2022). https://doi.org/10.1007/s40618-021-01691-5
37. Oróstica L, García P, Vera C, García V, Romero C, Vega M. Effect of TNF-α on Molecules Related to the Insulin Action in Endometrial Cells Exposed to Hyperandrogenic and Hyperinsulinic Conditions Characteristics of Polycystic Ovary Syndrome. Reprod Sci. 2018 Jul;25(7):1000-1009. doi: 10.1177/1933719117732157. Epub 2017 Sep 25. PMID: 28946816.
38. Oróstica, L., Poblete, C., Romero, C. et al. Pro-Inflammatory Markers Negatively Regulate IRS1 in Endometrial Cells and Endometrium from Women with Obesity and PCOS. Reprod. Sci. 27, 290–300 (2020). https://doi.org/10.1007/s43032-019-00026-3
39. Nair S, Nguyen H, Salama S, Al-Hendy A. Obesity and the Endometrium: Adipocyte-Secreted Proinflammatory TNF α Cytokine Enhances the Proliferation of Human Endometrial Glandular Cells. Obstet Gynecol Int. 2013;2013:368543. doi: 10.1155/2013/368543. Epub 2013 Oct 30. PMID: 24288542; PMCID: PMC3832969.
40. Verena Wieser, Samira Abdel Azim, Susanne Sprung, Katharina Knoll, Johanna Kögl, Hubert Hackl, Christian Marth, Alain G Zeimet, Heidelinde Fiegl, TNFα signalling predicts poor prognosis of patients with endometrial cancer, Carcinogenesis, Volume 41, Issue 8, August 2020, Pages 1065–1073, https://doi.org/10.1093/carcin/bgaa034
41. Magagnini, M.C.; Condorelli, R.A.; Cimino, L.; Cannarella, R.; Aversa, A.; Calogero, A.E.; La Vignera, S. Does the Ketogenic Diet Improve the Quality of Ovarian Function in Obese Women? Nutrients 2022, 14, 4147. https://doi.org/10.3390/nu14194147
42. Ujvari D, Hulchiy M, Calaby A, Nybacka Å, Byström B, Hirschberg AL. Lifestyle intervention up-regulates gene and protein levels of molecules involved in insulin signaling in the endometrium of overweight/obese women with polycystic ovary syndrome. Hum Reprod. 2014 Jul;29(7):1526-35. doi: 10.1093/humrep/deu114. Epub 2014 May 19. PMID: 24842895
43. Camajani, E., Feraco, A., Verde, L. et al. Ketogenic Diet as a Possible Non-pharmacological Therapy in Main Endocrine Diseases of the Female Reproductive System: A Practical Guide for Nutritionists. Curr Obes Rep 12, 231–249 (2023). https://doi.org/10.1007/s13679-023-00516-1
44. Caroline W Cohen, Kevin R Fontaine, Rebecca C Arend, Ronald D Alvarez, Charles A Leath, Warner K Huh, Kerri S Bevis, Kenneth H Kim, John M Straughn, Barbara A Gower, A Ketogenic Diet Reduces Central Obesity and Serum Insulin in Women with Ovarian or Endometrial Cancer,The Journal of Nutrition,Volume 148, Issue 8,2018, Pages 1253-1260, ISSN 0022-3166, https://doi.org/10.1093/jn/nxy119.
45. Barrea, L., Caprio, M., Watanabe, M., Cammarata, G., Feraco, A., Muscogiuri, G., … Savastano, S. (2023). Could very low-calorie ketogenic diets turn off low grade inflammation in obesity? Emerging evidence. Critical Reviews in Food Science and Nutrition, 63(26), 8320–8336. https://doi.org/10.1080/10408398.2022.2054935
46. Rondanelli, M., Perna, S., Ilyas, Z. et al. Effect of very low-calorie ketogenic diet in combination with omega-3 on inflammation, satiety hormones, body composition, and metabolic markers. A pilot study in class I obese subjects. Endocrine 75, 129–136 (2022). https://doi.org/10.1007/s12020-021-02860-5
47. Assia Berrani, Ilias Marmouzi, Abdelhakim Bouyahya, Mourad Kharbach, Maha El Hamdani, Meryem El Jemli, Aicha Lrhorfi, Meryem Zouarhi, My El Abbes Faouzi, Rachid Bengueddour, "Phenolic Compound Analysis and Pharmacological Screening of Vitex agnus-castus Functional Parts", BioMed Research International, vol. 2021, Article ID 6695311, 10 pages, 2021. https://doi.org/10.1155/2021/6695311
48. Moini Jazani A, Nasimi Doost Azgomi H, Nasimi Doost Azgomi A, Nasimi Doost Azgomi R. A comprehensive review of clinical studies with herbal medicine on polycystic ovary syndrome (PCOS). Daru. 2019 Dec;27(2):863-877. doi: 10.1007/s40199-019-00312-0. Epub 2019 Nov 18. PMID: 31741280; PMCID: PMC6895349.
49. Hamza, Amal H1,2,; AlBishri, Widad M1; Alfaris, Mona H3. Effect of Vitex agnus-castus plant extract on polycystic ovary syndrome complications in experimental rat model. Asian Pacific Journal of Reproduction 8(2):p 63-69, March 2019. | DOI: 10.4103/2305-0500.254647
50. Naiyereh Haerifar1 ID , Gholamhassan Vaezi1* ID , Zahra Ghatreh Samani2 Shaker Salari Lak3 The Effect of Vitex Agnus Castus Extract on the Blood Level of Prolactin, Sex Hormones Levels, and the Histological eISSN 2148-9696
51. Włodarczyk, M.; Ciebiera, M.; Nowicka, G.; Łoziński, T.; Ali, M.; Al-Hendy, A. Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases—Focus on Epigenetic Mechanisms. Nutrients 2024, 16, 559. https://doi.org/10.3390/nu16040559
52. Farhadian, Maryam1,2; Barati, Somayeh3; Mahmoodi, Minoo3; Mosleh, Amir Barati4; Yavangui, Mahnaz4,. Comparison of Green Tea and Metformin Effects on Anthropometric Indicators in Women with Polycystic Ovarian Syndrome: A Clinical Trial Study. Journal of Reports in Pharmaceutical Sciences 9(1):p 97-103, Jan–Jun 2020. | DOI: 10.4103/jrptps.JRPTPS_14_19
53. Gonzales, A.M., Orlando, R.A. Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes. Nutr Metab (Lond) 5, 17 (2008). https://doi.org/10.1186/1743-7075-5-17
54. Kheiripour N, Khodamoradi Z, Ranjbar A, Borzouei S. The positive effect of short-term nano-curcumin therapy on insulin resistance and serum levels of afamin in patients with metabolic syndrome. Avicenna J Phytomed. 2021 Mar-Apr;11(2):146-153. PMID: 33907673; PMCID: PMC8051321.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Nataliia Mokrianyn
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 200
Number of citations: 0
